Literature DB >> 7438468

The effect of oestrogens on human calcitonin secretion after calcium infusion in elderly female subjects.

S Morimoto, M Tsuji, Y Okada, T Onishi, Y Kumahara.   

Abstract

The effect of oestrogen administration (4-6 weeks) on the response of human calcitonin (hCT) secretion to 5 min calcium infusions was studied in ten elderly women. There was no significant difference in mean basal plasma hCT levels before and after oestrogen administration. However, the mean increment in plasma hCT in response to calcium infusion (delta hCT) increased significantly (P < 0.001) from 21.9 +/- 6.6 (mean +/- SE) before treatment, to 79.6 +/- 15.5 ng/l after oestrogen administration. Mean serum calcium levels decreased significantly (P < 0.001) from 2.42 +/- 0.06 before to 2.19 +/- 0.07 mmol/l after oestrogen treatment. Mean plasma immunoreactive PTH (iPTH) levels increased significantly (P < 0.05) from 521 +/- 41 before to 696 +/- 96 ng/l after oestrogen treatment. To exclude out the possibility that the decreased serum calcium level itself might have influenced delta hCT, 1 alpha-hydroxycholecalciferol (1 alpha-OH-D3) was administered with oestrogens. While this resulted in a slight increase in serum calcium level, there was no significant difference in delta hCT in response to calcium infusion following oestrogen treatment alone, and after combination therapy of oestrogen and 1 alpha-OH-D3. The primary action of administered oestrogen may be in stimulating hCT secretion which results in a decrease in plasma calcium concentration and an increase in plasma iPTH level.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438468     DOI: 10.1111/j.1365-2265.1980.tb01034.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

1.  Calcitonin and estrogens.

Authors:  D Agnusdei; R Civitelli; A Camporeale; C Gennari
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

2.  Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women.

Authors:  M I Whitehead; N M Shennan; J C Stevenson
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-21

3.  Treatment of psoriasis vulgaris by oral administration of 1 alpha-hydroxyvitamin D3--open-design study.

Authors:  S Morimoto; K Yoshikawa; T Kozuka; Y Kitano; S Imanaka; K Fukuo; E Koh; T Onishi; Y Kumahara
Journal:  Calcif Tissue Int       Date:  1986-09       Impact factor: 4.333

4.  Topical administration of 1,25-dihydroxyvitamin D3 for psoriasis: report of five cases.

Authors:  S Morimoto; T Onishi; S Imanaka; H Yukawa; T Kozuka; Y Kitano; K Yoshikawa; Y Kumahara
Journal:  Calcif Tissue Int       Date:  1986-02       Impact factor: 4.333

5.  Effect of estrogens and phosphorus depletion on plasma calcitonin in the rat.

Authors:  B D Catherwood; T Onishi; L J Deftos
Journal:  Calcif Tissue Int       Date:  1983-07       Impact factor: 4.333

6.  Influence of estrogens on calcitonin secretion.

Authors:  G C Isaia; M Mussetta; M Massobrio; A Sciolla; M Gallo; G M Molinatti
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

7.  Calcitonin reserve in healthy women and patients with postmenopausal osteoporosis.

Authors:  R Pérez Cano; M J Montoya; R Moruno; A Vazquez; F Galan; M Garrido
Journal:  Calcif Tissue Int       Date:  1989-10       Impact factor: 4.333

8.  Biochemical short-term changes produced by hormonal replacement therapy.

Authors:  J F Aloia; A Vaswani; J K Yeh; D M McGowan; P Ross
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

9.  Effect of ipriflavone on bone mineral density and calcium-related factors in elderly females.

Authors:  S Nakamura; S Morimoto; S Takamoto; T Onishi; K Fukuo; E Koh; S Kitano; Y Miyashita; O Yasuda; M Tamatani
Journal:  Calcif Tissue Int       Date:  1992       Impact factor: 4.333

10.  Calcitonin secretion in children with insulin-dependent diabetes mellitus.

Authors:  G Saggese; S Bertelloni; G I Baroncelli; P Ghirri
Journal:  Eur J Pediatr       Date:  1991-05       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.